ClinicalTrials.gg
RecruitingNCT05800600Iron-RANCUpdated May 22, 2026

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

A Phase 2 interventional study of Venofer in Anemia, sponsored by Fox Chase Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Fox Chase Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing iron sucrose in Anemia — 1 open to participants now, 1 under way, none of them phase 3. iron sucrose · Anemia.

Planned enrollment
22nd of 29
34 · median 80
Started
2023
with 1 other
Phase 2
5 of 29
1 open now
Registered
26th of 29
by date
Lead sponsor
1 of 29
Fox Chase Cancer Center

Among the 29 studies testing iron sucrose in Anemia, this one is the 22nd largest by planned enrollment, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 26th registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 29 studies testing iron sucrose in Anemia is open now, in 1 country.

By country, each count listing its studies:

About iron sucrose

iron sucrose: first FDA approval 2000 (VENOFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing iron sucrose in Anemia, or all of them as a file.
02

Study summary

This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.

Read the detailed description

This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection. The concomitant use of radiation and immunotherapy as part of the neoadjuvant protocol is allowed in this protocol. The study is designed to evaluate the efficacy of iron infusions in reducing blood transfusion frequency and improving hemoglobin levels prior to surgical intervention.

03

Conditions studied

  • Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients > 18 years
  • Patients undergoing chemotherapy, including radiation and/or immunotherapy, with intent for curative surgical resection for breast, thoracic, gastrointestinal (GI) or genitourinary (GU) .
  • Anemia defined as \<10.5 g/dL during chemotherapy.
  • Iron storage levels of ferritin \<500 ng/mL and iron saturation \<35%
  • Ability to understand and willingness to sign a written and HIPAA consent document

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of anemia at the time of cycle 1 day 1 of chemotherapy, \< 11.0 g/dL, uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic new/exacerbated congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Prior parenteral iron infusion in the past 4 weeks
  • The use of erythropoietin stimulating agents within 4 weeks unless chronic needs due to CKD
  • Concurrent systemic infection at the time of enrollment.
  • Known to Iron sucrose
  • Pregnant or breast feeding. Refer to section 4.4 for further detail.
  • Anemia from another established etiology (i.e MDS, Myeloma)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Venofer treatment

    Venofer (iron-sucrose) 200mg (5 days) every week administered as an IV infusion

    Drug: Venofer

Interventions

  • DrugIron sucroseStudies of Iron sucroseIron sucrose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour

06

What researchers measure

Primary outcomes

  1. Mean change from baseline to highest Hgb value

    To evaluate the efficacy of iron infusions in improving chemotherapy-induced anemia by improving the hemoglobin of patients undergoing neoadjuvant chemotherapy. Mean change from baseline to highest Hgb value observed six weeks after last iron infusion, before day of surgery.

    Time frame: 6 weeks

Secondary outcomes

  1. Number of transfusions during neo-adjuvant period

    To evaluate the efficacy of iron infusions in improving chemotherapy-induced anemia and minimizing red blood cell transfusions in patients undergoing neoadjuvant chemotherapy.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Feb 2027, 46 months after the start.

Of 88 phase 2 interventional studies under Anemia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
Apr 5, 2023
StartActual
Mar 15, 2023
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05800600
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Mar 15, 2023
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
May 22, 2026

Study contacts

Ryan Romasko
Contact
ryan.romasko@fccc.edu
2678388380
Iberia Sosa, MD
principal investigator · Fox Chase Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron sucrose

Start the discussion